Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
View original at finance.yahoo.comPfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFI…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Prior to December 20, 2024, there were no approved biomarker-driven therapies specifically indicated for people with previously untreated BRAF V600E-mutant metastatic colorectal cancer
80% confidenceThe BREAKWATER trial demonstrates clinically meaningful and statistically significant results, which show potential flexibility in chemotherapy backbone for patients with BRAF V600E-mutant metastatic colorectal cancer
80% confidenceThese results underscore the potential of BRAFTOVI as a standard of care for patients with this aggressive cancer and reflect commitment to advancing precision medicine options
80% confidenceThese results represent a great advance for patients with BRAF V600E-mutant metastatic colorectal cancer with significantly increased response compared to FOLFIRI with or without bevacizumab, and these responses were rapid and durable
80% confidenceThe trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
80% confidenceThese data further strengthen the potential utility of BRAFTOVI for patients with BRAF V600E-mutant metastatic colorectal cancer with significant improvement in response rates reflecting meaningful clinical benefit
80% confidence